Literature DB >> 2896056

A novel interaction between dynorphin(1-13) and an N-methyl-D-aspartate site.

R M Caudle1, L Isaac.   

Abstract

Dynorphin injected intrathecally in the rat results in a neurotoxicity behaviorally expressed as an irreversible loss of the thermally evoked tail-flick reflex. The excitatory amino acid antagonists DL-2-amino-5-phosphonovalerate (APV) and gamma-D-glutamylglycine (DGG) blocked the loss of the tail-flick reflex. The order of potency (APV greater than DGG) suggests that the N-methyl-D-aspartate (NMDA) subclass of excitatory amino acid receptors participate in the neurotoxicity. Additionally, intrathecal injection of APV results in a reversible loss of the tail-flick reflex, whereas with DGG doses which block the tail-flick reflex also result in hindlimb paralysis. These data suggest that neurotransmission in the tail-flick reflex pathway is, in part, mediated by NMDA receptors. From these and previous findings it was concluded that dynorphin neurotoxicity results from enhanced, excitotoxic, transmission across these synapses utilizing NMDA receptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2896056     DOI: 10.1016/0006-8993(88)91628-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  13 in total

Review 1.  Central non-opioid physiological and pathophysiological effects of dynorphin A and related peptides.

Authors:  V K Shukla; S Lemaire
Journal:  J Psychiatry Neurosci       Date:  1992-09       Impact factor: 6.186

Review 2.  Dynorphin A analogs for the treatment of chronic neuropathic pain.

Authors:  Sara M Hall; Yeon Sun Lee; Victor J Hruby
Journal:  Future Med Chem       Date:  2016-01-29       Impact factor: 3.808

Review 3.  Pathobiology of dynorphins in trauma and disease.

Authors:  Kurt F Hauser; Jane V Aldrich; Kevin J Anderson; Georgy Bakalkin; MacDonald J Christie; Edward D Hall; Pamela E Knapp; Stephen W Scheff; Indrapal N Singh; Bryce Vissel; Amina S Woods; Tatiana Yakovleva; Toni S Shippenberg
Journal:  Front Biosci       Date:  2005-01-01

4.  Decoy peptides that bind dynorphin noncovalently prevent NMDA receptor-mediated neurotoxicity.

Authors:  Amina S Woods; Rafal Kaminski; Murat Oz; Yun Wang; Kurt Hauser; Robin Goody; Hay-Yan J Wang; Shelley N Jackson; Peter Zeitz; Karla P Zeitz; Dorota Zolkowska; Raf Schepers; Michael Nold; Jens Danielson; Astrid Gräslund; Vladana Vukojevic; Georgy Bakalkin; Allan Basbaum; Toni Shippenberg
Journal:  J Proteome Res       Date:  2006-04       Impact factor: 4.466

Review 5.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

6.  Nor-Binaltorphimine Blocks the Adverse Effects of Morphine after Spinal Cord Injury.

Authors:  Miriam Aceves; Eric A Bancroft; Alejandro R Aceves; Michelle A Hook
Journal:  J Neurotrauma       Date:  2016-11-04       Impact factor: 5.269

7.  Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice.

Authors:  M Hiramatsu; K Inoue; A Ambo; Y Sasaki; T Kameyama
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 8.  Spinal opioid systems in inflammation.

Authors:  L Stanfa; A Dickenson
Journal:  Inflamm Res       Date:  1995-06       Impact factor: 4.575

9.  Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance.

Authors:  Mei Xu; Michael Petraschka; Jay P McLaughlin; Ruth E Westenbroek; Marc G Caron; Robert J Lefkowitz; Traci A Czyzyk; John E Pintar; Gregory W Terman; Charles Chavkin
Journal:  J Neurosci       Date:  2004-05-12       Impact factor: 6.167

Review 10.  Opioid administration following spinal cord injury: implications for pain and locomotor recovery.

Authors:  Sarah A Woller; Michelle A Hook
Journal:  Exp Neurol       Date:  2013-03-15       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.